Suppr超能文献

连续性静脉滴注万古霉素在接受连续性肾脏替代治疗的脓毒症患者中的应用。

Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy.

机构信息

Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles-ULB, Route de Lennik 808, 1070 Brussels, Belgium.

出版信息

Int J Antimicrob Agents. 2013 Mar;41(3):261-6. doi: 10.1016/j.ijantimicag.2012.10.018. Epub 2013 Jan 9.

Abstract

Vancomycin is frequently administered as a continuous infusion to treat severe infections caused by Gram-positive bacteria. Previous studies have suggested a loading dose of 15 mg/kg followed by continuous infusion of 30 mg/kg in patients with normal renal function; however, there are no dosing recommendations in patients with renal failure undergoing continuous renal replacement therapy (CRRT). Data from all adult septic patients admitted to a Department of Intensive Care over a 3-year period in whom vancomycin was given as a continuous infusion were reviewed. Patients were included if they received vancomycin for ≥48h during CRRT. Vancomycin levels were obtained daily. During the study period, 85 patients (56 male; mean age 65±15 years; weight 85±24kg) met the inclusion criteria. Median (interquartile range) APACHE II and SOFA scores were 24 (20-29) and 11 (7-14), respectively, and the overall mortality rate was 59%. Mean vancomycin doses were 16.4±6.4 (loading dose), 23.5±8.1 (Day 1), 23.2±7.4 (Day 2) and 23.3±11.0 (Day 3) mg/kg, resulting in blood concentrations of 24.7±9.0 (Day 1), 26.0±8.1 (Day 2) and 27.7±9.3 (Day 3) μg/mL. On Day 1, 43 patients (51%) had adequate drug concentrations (20-30 μg/mL), 17 (20%) had levels >30 μg/mL and 25 (29%) had levels <20 μg/mL. Most patients with adequate drug concentrations received a daily dose of 16-35 mg/kg. The intensity of CRRT directly influenced vancomycin concentrations on Day 1 of therapy.

摘要

万古霉素常被用作连续输注,以治疗由革兰阳性菌引起的严重感染。先前的研究表明,肾功能正常的患者给予负荷剂量 15mg/kg 后,持续输注 30mg/kg;但在接受连续肾脏替代治疗(CRRT)的肾衰竭患者中,尚无剂量推荐。回顾了在 3 年内入住重症监护病房的所有成年败血症患者的数据,这些患者在接受 CRRT 的过程中接受了万古霉素的连续输注。如果患者在 CRRT 期间接受万古霉素治疗≥48 小时,则将其纳入研究。每天测定万古霉素水平。在研究期间,85 例患者(56 例男性;平均年龄 65±15 岁;体重 85±24kg)符合纳入标准。中位数(四分位距)APACHE II 和 SOFA 评分分别为 24(20-29)和 11(7-14),总体死亡率为 59%。万古霉素平均剂量为 16.4±6.4(负荷剂量)、23.5±8.1(第 1 天)、23.2±7.4(第 2 天)和 23.3±11.0(第 3 天)mg/kg,血药浓度分别为 24.7±9.0(第 1 天)、26.0±8.1(第 2 天)和 27.7±9.3(第 3 天)μg/mL。第 1 天,43 例(51%)患者药物浓度足够(20-30μg/mL),17 例(20%)患者药物浓度>30μg/mL,25 例(29%)患者药物浓度<20μg/mL。大多数药物浓度足够的患者接受了 16-35mg/kg/d 的日剂量。CRRT 的强度直接影响治疗第 1 天的万古霉素浓度。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验